Valneva launches COVID-19 vaccine manufacturing in Scotland: officials
A coronavirus vaccine candidate developed by French biotechnology firm Valneva has launched manufacturing in Scotland, the corporate introduced Thursday.
Valneva expects to readout outcomes from an ongoing early section trial in April, in keeping with an organization statement. The Phase I/II trial began in mid-December, testing three dose ranges amongst 150 wholesome adults aged 18 to 55. The candidate, coined VLA2001, entails an inactivated, adjuvanted vaccine and, if accepted, could be administered in two doses, three weeks aside.
“We are extremely pleased to have achieved these two important milestones in such a short period of time,” Thomas Lingelbach, chief govt officer of Valneva, stated in the assertion. “Our team in Scotland have done an amazing job to get manufacturing started so quickly.”
FIRST US CASES OF SOUTH AFRICAN CORONAVIRUS VARIANT IDENTIFIED IN SOUTH CAROLINA
Britain’s Health Secretary, Matt Hancock, took to Twitter Thursday to laud the information. The U.Ok. has already approved, and continues to distribute, three coronavirus vaccines, and marked the primary nation worldwide to start vaccinations for a product developed by AstraZeneca.
“The Valneva vaccine will be another vital tool in our fight against the virus if approved,” Hancock wrote. “The start of manufacturing in Livingston today is another fantastic example of the strength of our Union, as we work together as one United Kingdom to tackle the virus
PEOPLE WITH UK CORONAVIRUS VARIANT MORE LIKELY TO REPORT THESE SYMPTOMS: SURVEY
Prime Minister Boris Johnson also celebrated the news, noting that the manufacturing process will create 100 jobs.
Valneva previously announced an agreement with the U.K. to provide 190 million doses, and upon approval, plans to send 60 million doses to the U.K. in the latter half of 2021. Valneva also announced “superior discussions” with the E.U. to supply up to 60 million doses.
“We consider that our vaccine, assuming profitable improvement, could make a serious contribution in the UK and past,” Lingelbach stated.
